Creating therapeutic products to degrade disease-causing proteins



Pin Pharmaceuticals, Inc. is a privately held, early stage biotechnology company developing protein degradation therapeutics applicable to various indications such as cancer, autoimmune diseases, and infectious diseases, using our proprietary proteolysis platform technology.

We are on a mission to be a pioneer in revolutionizing current therapies for patients with unmet needs. Our focused vision is to develop a pipeline of chemical agents targeting critical disease-causing proteins that have been undruggable by conventional approaches.






Pin Pharmaceuticals, Inc. is continuously building a team of drug discovery experts from diverse backgrounds with proven track records of successfully developing drugs and bringing them to market.


We have established a highly productive working relationships with consultants, advisors, and CROs in the USA, UK, Germany, India, China, and Korea.

Hyunsun (Joe) Jo

Founder & Chairman of the Board of Directors

Hyunsun (Joe) Jo is an energetic and visionary entrepreneur and founded Pin Companies. Joe also serves as the CEO of Pin Therapeutics, Inc., in Korea.  Previously, he served as CEO of LabQnA and Embedbio and as president of the Korean Life Scientists (KOLIS) in the San Francisco Bay area.

Joe holds a PhD in molecular biology from the Seoul National University and received his postdoctoral training at the J David Gladstone Institute, University of California, San Francisco where his research focused on epigenetic regulation in the mitochondria and the mechanism of rejuvenation.

Namheon (Brandon) Lee

Business Operations

Namheon (Brandon) Lee is responsible for various activities in business operations including human resources and accounting. He is the go-to-person driving synergies across the cross-functional teams for achieving operational excellence. Previously, he worked at Pin Therapeutics as a Director of Business Operations and has various industrial experiences including P&G and Hyundai Motors.

Brandon holds a PhD in mechanical engineering from University of Cincinnati and received his postdoctoral training in the Heart Institute at the Cincinnati Children’s Hospital Medical Center.

Working Together


Pin Pharmaceuticals, Inc. is a wholly-owned subsidiary of Pin Therapeutics, Inc., a research-oriented biotechnology company in the Republic of Korea. We work very closely with our Korean counterparts to support their drug discovery efforts.



We are aggressively building a portfolio of disease-related protein degraders by leveraging our PIN Platform. We have wholly-owned programs for cancer, autoimmune diseases, and infectious diseases in our internal pipeline.  


We plan to establish and expand potential R&D partnerships to maximize our platform technology to expedite new treatment modalities applicable to current unmet needs.


Contact Us

Email us with any question or inquiry. We will get back to you as soon as we can.

Message sent!

Thanks for your interest.